Literature DB >> 20421567

Oncolytic viruses move forward in clinical trials.

Karen Rowan.   

Abstract

Mesh：

Year:  2010        PMID： 20421567     DOI： 10.1093/jnci/djq165

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  23 in total

1.  Simulations show that virus assembly and budding are facilitated by membrane microdomains.

Authors:  Teresa Ruiz-Herrero; Michael F Hagan
Journal:  Biophys J       Date:  2015-02-03       Impact factor: 4.033

2.  Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Authors:  Jay D Naik; Christopher J Twelves; Peter J Selby; Richard G Vile; John D Chester
Journal:  Clin Cancer Res       Date:  2011-05-16       Impact factor: 12.531

3.  Patent trend and competitive analysis of cancer immunotherapy in the United States.

Authors:  Chia-Lin Pan; Feng-Chi Chen
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

4.  Why Enveloped Viruses Need Cores-The Contribution of a Nucleocapsid Core to Viral Budding.

Authors:  Guillermo R Lázaro; Suchetana Mukhopadhyay; Michael F Hagan
Journal:  Biophys J       Date:  2018-02-06       Impact factor: 4.033

5.  Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.

Authors:  Simon Leveille; Marie-Line Goulet; Brian D Lichty; John Hiscott
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

6.  M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells.

Authors:  Zahra Gray; Alijan Tabarraei; Abdolvahab Moradi; Mohamad R Kalani
Journal:  Mol Biol Rep       Date:  2019-04-20       Impact factor: 2.316

7.  NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.

Authors:  Yotam Bar-On; Yoav Charpak-Amikam; Ariella Glasner; Batya Isaacson; Alexandra Duev-Cohen; Pinchas Tsukerman; Alexander Varvak; Michal Mandelboim; Ofer Mandelboim
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

8.  DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Authors:  Katrin Friedrich; Jan Rh Hanauer; Steffen Prüfer; Robert C Münch; Iris Völker; Christodoulos Filippis; Christian Jost; Kay-Martin Hanschmann; Roberto Cattaneo; Kah-Whye Peng; Andreas Plückthun; Christian J Buchholz; Klaus Cichutek; Michael D Mühlebach
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

9.  BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.

Authors:  Sara Samuel; Vladimir Beljanski; Julien Van Grevenynghe; Stephanie Richards; Fethia Ben Yebdri; Zhong He; Carmen Nichols; S Mehdi Belgnaoui; Courtney Steel; Marie-Line Goulet; April Shamy; Dawn Brown; Guillermo Abesada; Elias K Haddad; John Hiscott
Journal:  Mol Ther       Date:  2013-05-21       Impact factor: 11.454

10.  Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.

Authors:  Laura Shulak; Vladimir Beljanski; Cindy Chiang; Sucharita M Dutta; Julien Van Grevenynghe; S Mehdi Belgnaoui; Thi Lien-Anh Nguyên; Thomas Di Lenardo; O John Semmes; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.